TGM2 and chronic kidney disease: Human disease expression data [12, 13] and studies using knock-out (KO) animals [11, 14], together with studies on small-molecule inhibitors [15, 16] and small interfering ribonucleic acid (siRNA) [12, 17], have suggested TG2 as a favorable therapeutic target in kidneys [18], lungs [19], liver [20], and heart [15]; this concept is perhaps best supported by data in chronic kidney disease (CKD) [18, 21, 22].